肿瘤坏死因子相关诱导凋亡配体联合丝裂霉素C治疗膀胱癌的实验研究
|
摘要
第一部分肿瘤坏死因子相关诱导凋亡配体以及联合丝裂霉素C对人膀胱癌细胞作用的体外实验
目的检测肿瘤坏死因子相关诱导凋亡配体(Tumor necrosis factor relatedapoptosis-inducing ligand,TRAIL)对人膀胱癌细胞株体外生长的抑制作用和凋亡作用,以及TRAIL联合丝裂霉素C(MMC)治疗膀胱癌的协同作用。
方法人膀胱癌细胞株T24、5637体外培养。将T24、5637膀胱癌细胞接种至96孔培养板,培养24h后分别加入浓度为1、10、100μg/L的TRAIL,0.1、1.0、10.0mg/L的MMC,不同浓度TRAIL和MMC作用24h,采用噻唑蓝比色(4,5-dimethy thiazoleor 2,5-diphenyl tetrazolium bromide,MTT)法分别检测膀胱癌细胞的生存率,并将单独用TRAIL、MMC与TRAIL联合MMC对膀胱癌细胞株T24、5637的生长抑制情况进行比较;将T24及5637膀胱癌细胞接种至12孔板,培育24小时后加入不同浓度的TRAIL、MMC、TRAIL联合MMC并作用12h,用流式细胞术检测不同处理组膀胱癌细胞的凋亡率和死亡率,并将单独用TRAIL、MMC与TRAIL联合MMC组进行比较。
结果TRAIL能有效抑制人膀胱癌细胞株T24、5637的生长。①MTT实验结果:1、10、100μg/L的TRAIL对膀胱癌T24细胞的抑制率分别为26.4%、29.3%和37.7%,与无药物组比较差异有显著性(P＜0.01)。三种浓度的TRAIL对膀胱癌5637细胞的抑制率分别为13.7%、21.9%和59.1%,1μg/L TRAIL组与无药物组比较差异无显著性(P＞0.05),10、100μg/L TRAIL组与无药物组比较差异有显著性(P＜0.01)。10.0mg/LMMC对膀胱癌T24、5637细胞的抑制率分别为36.0%、26.7%;而100μg/L TRAIL联合10.0 mg/L MMC组对膀胱癌T24、5637细胞的抑制率分别达到58.4%、90.7%,联合用药有明显的协同作用,与单纯100μg/L TRAIL组、单纯10.0 mg/L MMC组相比差异有显著性(P＜0.05)。②流式细胞术检测结果:100μg/L TRAIL引起膀胱癌T24、5637细胞的凋亡,凋亡率分别为20.1%、47.5%,与无药物组1.9%、5.1%的凋亡率相比差异有显著性(P＜0.01);10.0mg/L MMC对膀胱癌T24、5637细胞的凋亡率分别为13.1%、18.1%;而100μg/L TRAIL联合10.0 mg/L MMC组对膀胱癌T24、5637细胞的凋亡率分别达到41.5%、61.5%,两者有明显的协同作用,与单纯100μg/L TRAIL组、单纯10.0 mg/L MMC组相比差异有显著性(P＜0.05)。
结论在体外实验中,①TRAIL能有效地抑制人膀胱癌细胞株T24、5637的生长,诱导人膀胱癌细胞株T24、5637凋亡;②TRAIL联合MMC抑制人膀胱癌细胞株T24、5637生长和诱导人膀胱癌细胞株T24、5637凋亡具有协同作用。
第二部分Ad-TRAIL以及联合MMC对膀胱癌作用的在体实验
目的:建立人膀胱癌细胞株T24 BALB/c-nu小鼠皮下移植瘤模型;在体研究真核表达载体Ad-TRAIL转染T24膀胱癌组织的效果及其对膀胱癌的治疗作用,以及联合MMC治疗膀胱癌的协同作用。
方法:①人膀胱癌细胞株T24体外培养。6周龄免疫缺陷小鼠(BALB/c-nu)共5只。在超净台内将小鼠右侧前肢根部背侧皮肤用75%酒精消毒后皮下接种0.2ml浓度为1×10~7个/ml的T24人膀胱癌细胞株悬液,等上述接种小鼠的肿瘤长至直径1cm大小时,处死小鼠,切取肿瘤。再切开肿瘤,取质地均匀处组织,切成2mm~3,10～15mg大小,分别移植至40只6周龄BALB/c-nu小鼠右前肢根部背侧皮下,每只小鼠移植1块。移植方法:先用75%酒精消毒移植处皮肤,切一0.4cm大小的皮肤切口,分离皮下组织,将组织块植入皮下,0号线缝合皮肤切口。继续按常规饲养小鼠并观察注射部位的变化。②上述BALB/c-nu小鼠模型40只,肿瘤长到0.4～0.6cm后随机分成四组,分别为单用MMC组(A组):腹腔注射0.1g/L MMC(10μl/g体重),连续注射7d;瘤内注射5×10~8pfu/ml Ad空载体0.1ml×3处,分别注射于肿瘤的4、8、12点,1次/2d,共3次;单用Ad-TRAIL组(B组):腹腔注射PBS(10μl/g体重)×7d,瘤内注射5×10~8pfu/mlAd-TRAIL 0.1ml×3处,1次/2d,共3次;联合Ad-TRAIL和MMC组(C组):瘤内注射Ad-TRAIL同B组,腹腔注射MMC同A组;对照组(D组):腹腔注射PBS(10μl/g体重)×7d,瘤内注射5×10~8pfu/ml Ad空载体0.1ml×3处,1次/2d,共3次。给药结束2周后脱颈处死荷瘤鼠,测量小鼠体重,所荷肿瘤的直径和重量。取出肿瘤制成常规病理切片观察。用RT-PCR和Western blot测量肿瘤组织内TRAIL mRNA及TRAIL蛋白的表达水平。
结果:①第一批5只小鼠,有3只荷瘤模型建立成功,至细胞注射后50d,3只小鼠荷瘤直径达0.6～1.0cm,并经病理组织学证实;第二批40只小鼠肿瘤模型建立全部成功,成瘤率达100%,移植后4周所有小鼠肿瘤直径在0.4～0.6cm。②四组小鼠给药前体重及所荷肿瘤平均直径差异无统计学意义(P＞0.05);给药结束2周后,A、B、C组所荷肿瘤直径和重量均显著小于D组(P＜0.001),而C组又显著小于A、B组(P＜0.01),B组又显著小于A组(P＜0.001);A、C组体重均显著小于D组(P＜0.01),而B组和D组差异无统计学意义(P＞0.05);肿瘤组织病理切片镜下观察,组织坏死由多到少依次为C组、B组、A组和D组;B、C组肿瘤组织内均有TRAIL mRNA和TRAIL蛋白的表达,且两组间表达相对量差异无统计学意义(P＞0.05),而A、D组则无TRAIL mRNA和TRAIL蛋白的表达。
结论:①成功构建裸鼠人膀胱癌细胞株T24皮下移植瘤模型;②在体实验中,Ad-TRAIL能成功转染T24膀胱癌组织且表达TRAIL蛋白;③TRAIL对T24人膀胱癌裸鼠移植瘤具有明显的抑制作用,且TRAIL联合MMC具有协同抗膀胱癌作用。
PartⅠExperimental study of a combination of TRAIL and MMC on treatment of bladder cancer cell strains in vitro
Objective:To explore the effect of TRAIL(Tumor necrosis factor-related apoptosis-inducing ligand) on inhibition and apoptosis of bladder cancer cell strains T24 and 5637 in vitro,and to explore the anti-tumor synergistic effects of TRAIL and MMC on bladder cancer cell strains.
Methods:T24 and 5637 bladder cancer cell strains were employed in our study, 100μl of target cell suspension were added to each well of 96-well plates,by adding a concentration of 1,10,100μg/L TRAIL,0.1,1.0,10.0 mg/L mitomycin C(MMC) respectively.The bladder cancer cells were incubated for 24 hours with TRAIL,MMC and TRAIL combined with MMC at different concentration.MTT working solution was added to each culture well and calculated the survival rates of bladder cancer cells and compared the deference.Bladder cancer cell suspension was added to 12-well plates and incubated for 24h,and then incubated for 12 hours with TRAIL,MMC and TRAIL combined with MMC at different concentration.The rates of apoptosis and death of bladder cancer cells were detected by flow cytometry,and compared the deference within TRAIL group,MMC group and the group of TRAIL combined with MMC.
Results:TRAIL inhibited efficiently the growth of human bladder cancer cell strains T24,5637 significantly.①MTT experiment results:the growth inhibition rate(GIR) of 1,10,100μg/L TRAIL on bladder cancer T24 cell strain were 26.4%,29.3%and 37.7%, there was a significant difference(P＜0.01) to the non-drug group.The GIR of three concentrations of TRAIL on bladder tumor 5637 cell strain were 13.7%,21.9%and 59.1%, respectively.Compare to the group of non-drug,there was no significant difference to the group of 1μg/L TRAIL(P＞0.05),whereas there was a significant difference to the group 10,100μg/L TRAIL(P＜0.01).10.0mg/L MMC on bladder cancer T24,5637 cell strains, the GIR were 36.0%,26.7%,whereas 100μg/L TRAIL combined with 10.0mg/L MMC on the bladder tumor cell strains T24,5637,the GIR reached 58.4%,90.7%,respectively, There was significant difference to 100μg/L TRAIL and 10.0mg/L MMC,both have obvious synergy(P＜0.05).②the results of detecting by flow cytometry:100μg/L TRAIL induced bladder tumor cell strains T24,5637 apoptosis,apoptosis rates were 20.1%,47.5%, and there was a significant differences(P＜0.01) to the apoptosis rate 1.9%,5.1%of the group of non-drug;The apoptosis rates were 13.1%,18.1%,respectively.when use individually 10.0mg/L MMC on bladder cancer cell strains T24,5637;whereas 100μg/L TRAIL combined with 10.0mg/L MMC on the bladder tumor cell strains T24,5637,the apoptosis rate reached 41.5%,61.5%,respectively.There was significant difference to 100μg/L TRAIL and 10.0mg/L MMC,both have obvious synergy in two cell strains (p＜0.05).
Conclusions:In vitro,①TRAIL can effectively inhibit the growth of bladder cancer cell strains T24,5637,and it also can induce apoptosis in human bladder tumor cell strains T24,5637.②TRAIL can enhance the effect of MMC on inhibiting the growth of human bladder cancer cell strains T24,5637,and they also have the synergistic effect on induction of human bladder cancer cell strains apoptosis.
PartⅡThe effect of Ad-TRAIL and MMC on bladder tumors in vivo
Objective:To study the therapeutic effects of eukaryotic expression vector coding human tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) combined with Mitomycin C(MMC) on bladder carcinoma in vivo.
Methods:Methods:①T24 human bladder cancer cell strain cultivate in vitro.Five 6-week-old immune-deficient mice(BALB/c-nu),the roots of the right forelimb dorsal skin with 75%alcohol disinfection,then inoculated subcutaneously with 0.2ml concentration of 1×10~7/ml of the T24 human bladder cancer cell line suspension.Up to the tumor size of 1cm in diameter,the mice were sacrificed and tumors excised,check the texture uniformity of department organizations,and cut into about 2 mm~3,10～15mg size, 40 mice of 6-week-old BALB/c-nu were transplanted to subcutaneous dorsal roots of the right forelimb.Transplantation methods:using 75%alcohol disinfection of transplanted skin,cut the size of 0.4cm skin incision,separation of subcutaneous tissue,the subcutaneous tissue implants,0~# suture the skin incision line.Continue to conventional feeding mice and to observe changes in the injection site.②These 40 BALB/c-nu mice, tumor grow to 0.4～0.6cm were randomly divided into four groups,namely group MMC(A group):intraperitoneal injection of 0.1g/L MMC(10μl/g body weight) keep on 7d; intratumoral injection of 5×10~8 pfu/ml Ad empty vector 0.1ml×3,the tumors were injected in 4,8,12 points,1/2d,a total of 3 times;Group Ad-TRAIL(B group):abdominal injection of PB S(10μl/g)×7d,intratumoral injection of 5×10~8 pfu/ml Ad-TRAIL 0.1ml×3, 1/2d,a total of 3 times;Group MMC and Ad-TRAIL(C group):abdominal injection of MMC as the group A,intratumoral injection of Ad-TRAIL as the group B;group control (group D):intraperitoneal injection of PBS(10μl/g)×7d,intratumoral injection of 5×10~8 pfu/ml Ad empty vector 0.1ml×3 sites,1/2d,a total of 3 times.Two weeks after drug delivery,to measure mouse body weight,diameter and weight of tumors,observe the tumor cells under the microscope(×400),and measure the TRAIL mRNA and TRAIL protein expression within tumor tissue by using RT-PCR and western blot.
Results:①the first batch of five mice,has three tumor-bearing model of success,to cells after injection of 50d,3 tumor-beating mice diameter reach 0.6～1.0cm,and confirmed by histopathology;the second batch of 40 mice tumor model for all of the success of tumor rate was 100%,4 weeks after transplantation all mice tumor diameter are 0.4～0.6cm.②pre-delivery weight and the load average diameter of the tumor was no significant difference in four groups of mice(P＞0.05);Tumor diameter and weight of group A,B,C were significantly smaller than group D(P＜0.001)2 weeks after delivery, while the group C was significantly smaller than group A and B(P＜0.01),group B was significantly smaller than group A(P＜0.001);Weight of group A and C were significantly less than group D(P＜0.01),while there was no significant difference between group B and group D(P＞0.05);Under the microscope,the necrosis of tumor cells, group C＞B＞A＞D;TRAIL mRNA and TRAIL protein expressed in tumor cell within Group B and C,and the difference of expression of the relative volume of Group B and C was not statistically significance(P＞0.05),while group A and D did not express the TRAIL mRNA and TRAIL protein in tumor cells.
Conclusion:①Constructed successfully in nude mice of human bladder cancer cell strain T24 nude model;②Experiments in vivo,Ad-TRAIL was successful transfected into T24 bladder cancer and expressed TRAIL protein;③MMC and Ad-TRAIL have obvious inhibitory effect to T24 human bladder cancer in nude mice transplanted tumor,and both has synergistic effect with combination.
目的检测肿瘤坏死因子相关诱导凋亡配体(Tumor necrosis factor relatedapoptosis-inducing ligand,TRAIL)对人膀胱癌细胞株体外生长的抑制作用和凋亡作用,以及TRAIL联合丝裂霉素C(MMC)治疗膀胱癌的协同作用。
方法人膀胱癌细胞株T24、5637体外培养。将T24、5637膀胱癌细胞接种至96孔培养板,培养24h后分别加入浓度为1、10、100μg/L的TRAIL,0.1、1.0、10.0mg/L的MMC,不同浓度TRAIL和MMC作用24h,采用噻唑蓝比色(4,5-dimethy thiazoleor 2,5-diphenyl tetrazolium bromide,MTT)法分别检测膀胱癌细胞的生存率,并将单独用TRAIL、MMC与TRAIL联合MMC对膀胱癌细胞株T24、5637的生长抑制情况进行比较;将T24及5637膀胱癌细胞接种至12孔板,培育24小时后加入不同浓度的TRAIL、MMC、TRAIL联合MMC并作用12h,用流式细胞术检测不同处理组膀胱癌细胞的凋亡率和死亡率,并将单独用TRAIL、MMC与TRAIL联合MMC组进行比较。
结果TRAIL能有效抑制人膀胱癌细胞株T24、5637的生长。①MTT实验结果:1、10、100μg/L的TRAIL对膀胱癌T24细胞的抑制率分别为26.4%、29.3%和37.7%,与无药物组比较差异有显著性(P＜0.01)。三种浓度的TRAIL对膀胱癌5637细胞的抑制率分别为13.7%、21.9%和59.1%,1μg/L TRAIL组与无药物组比较差异无显著性(P＞0.05),10、100μg/L TRAIL组与无药物组比较差异有显著性(P＜0.01)。10.0mg/LMMC对膀胱癌T24、5637细胞的抑制率分别为36.0%、26.7%;而100μg/L TRAIL联合10.0 mg/L MMC组对膀胱癌T24、5637细胞的抑制率分别达到58.4%、90.7%,联合用药有明显的协同作用,与单纯100μg/L TRAIL组、单纯10.0 mg/L MMC组相比差异有显著性(P＜0.05)。②流式细胞术检测结果:100μg/L TRAIL引起膀胱癌T24、5637细胞的凋亡,凋亡率分别为20.1%、47.5%,与无药物组1.9%、5.1%的凋亡率相比差异有显著性(P＜0.01);10.0mg/L MMC对膀胱癌T24、5637细胞的凋亡率分别为13.1%、18.1%;而100μg/L TRAIL联合10.0 mg/L MMC组对膀胱癌T24、5637细胞的凋亡率分别达到41.5%、61.5%,两者有明显的协同作用,与单纯100μg/L TRAIL组、单纯10.0 mg/L MMC组相比差异有显著性(P＜0.05)。
结论在体外实验中,①TRAIL能有效地抑制人膀胱癌细胞株T24、5637的生长,诱导人膀胱癌细胞株T24、5637凋亡;②TRAIL联合MMC抑制人膀胱癌细胞株T24、5637生长和诱导人膀胱癌细胞株T24、5637凋亡具有协同作用。
第二部分Ad-TRAIL以及联合MMC对膀胱癌作用的在体实验
目的:建立人膀胱癌细胞株T24 BALB/c-nu小鼠皮下移植瘤模型;在体研究真核表达载体Ad-TRAIL转染T24膀胱癌组织的效果及其对膀胱癌的治疗作用,以及联合MMC治疗膀胱癌的协同作用。
方法:①人膀胱癌细胞株T24体外培养。6周龄免疫缺陷小鼠(BALB/c-nu)共5只。在超净台内将小鼠右侧前肢根部背侧皮肤用75%酒精消毒后皮下接种0.2ml浓度为1×10~7个/ml的T24人膀胱癌细胞株悬液,等上述接种小鼠的肿瘤长至直径1cm大小时,处死小鼠,切取肿瘤。再切开肿瘤,取质地均匀处组织,切成2mm~3,10～15mg大小,分别移植至40只6周龄BALB/c-nu小鼠右前肢根部背侧皮下,每只小鼠移植1块。移植方法:先用75%酒精消毒移植处皮肤,切一0.4cm大小的皮肤切口,分离皮下组织,将组织块植入皮下,0号线缝合皮肤切口。继续按常规饲养小鼠并观察注射部位的变化。②上述BALB/c-nu小鼠模型40只,肿瘤长到0.4～0.6cm后随机分成四组,分别为单用MMC组(A组):腹腔注射0.1g/L MMC(10μl/g体重),连续注射7d;瘤内注射5×10~8pfu/ml Ad空载体0.1ml×3处,分别注射于肿瘤的4、8、12点,1次/2d,共3次;单用Ad-TRAIL组(B组):腹腔注射PBS(10μl/g体重)×7d,瘤内注射5×10~8pfu/mlAd-TRAIL 0.1ml×3处,1次/2d,共3次;联合Ad-TRAIL和MMC组(C组):瘤内注射Ad-TRAIL同B组,腹腔注射MMC同A组;对照组(D组):腹腔注射PBS(10μl/g体重)×7d,瘤内注射5×10~8pfu/ml Ad空载体0.1ml×3处,1次/2d,共3次。给药结束2周后脱颈处死荷瘤鼠,测量小鼠体重,所荷肿瘤的直径和重量。取出肿瘤制成常规病理切片观察。用RT-PCR和Western blot测量肿瘤组织内TRAIL mRNA及TRAIL蛋白的表达水平。
结果:①第一批5只小鼠,有3只荷瘤模型建立成功,至细胞注射后50d,3只小鼠荷瘤直径达0.6～1.0cm,并经病理组织学证实;第二批40只小鼠肿瘤模型建立全部成功,成瘤率达100%,移植后4周所有小鼠肿瘤直径在0.4～0.6cm。②四组小鼠给药前体重及所荷肿瘤平均直径差异无统计学意义(P＞0.05);给药结束2周后,A、B、C组所荷肿瘤直径和重量均显著小于D组(P＜0.001),而C组又显著小于A、B组(P＜0.01),B组又显著小于A组(P＜0.001);A、C组体重均显著小于D组(P＜0.01),而B组和D组差异无统计学意义(P＞0.05);肿瘤组织病理切片镜下观察,组织坏死由多到少依次为C组、B组、A组和D组;B、C组肿瘤组织内均有TRAIL mRNA和TRAIL蛋白的表达,且两组间表达相对量差异无统计学意义(P＞0.05),而A、D组则无TRAIL mRNA和TRAIL蛋白的表达。
结论:①成功构建裸鼠人膀胱癌细胞株T24皮下移植瘤模型;②在体实验中,Ad-TRAIL能成功转染T24膀胱癌组织且表达TRAIL蛋白;③TRAIL对T24人膀胱癌裸鼠移植瘤具有明显的抑制作用,且TRAIL联合MMC具有协同抗膀胱癌作用。
PartⅠExperimental study of a combination of TRAIL and MMC on treatment of bladder cancer cell strains in vitro
Objective:To explore the effect of TRAIL(Tumor necrosis factor-related apoptosis-inducing ligand) on inhibition and apoptosis of bladder cancer cell strains T24 and 5637 in vitro,and to explore the anti-tumor synergistic effects of TRAIL and MMC on bladder cancer cell strains.
Methods:T24 and 5637 bladder cancer cell strains were employed in our study, 100μl of target cell suspension were added to each well of 96-well plates,by adding a concentration of 1,10,100μg/L TRAIL,0.1,1.0,10.0 mg/L mitomycin C(MMC) respectively.The bladder cancer cells were incubated for 24 hours with TRAIL,MMC and TRAIL combined with MMC at different concentration.MTT working solution was added to each culture well and calculated the survival rates of bladder cancer cells and compared the deference.Bladder cancer cell suspension was added to 12-well plates and incubated for 24h,and then incubated for 12 hours with TRAIL,MMC and TRAIL combined with MMC at different concentration.The rates of apoptosis and death of bladder cancer cells were detected by flow cytometry,and compared the deference within TRAIL group,MMC group and the group of TRAIL combined with MMC.
Results:TRAIL inhibited efficiently the growth of human bladder cancer cell strains T24,5637 significantly.①MTT experiment results:the growth inhibition rate(GIR) of 1,10,100μg/L TRAIL on bladder cancer T24 cell strain were 26.4%,29.3%and 37.7%, there was a significant difference(P＜0.01) to the non-drug group.The GIR of three concentrations of TRAIL on bladder tumor 5637 cell strain were 13.7%,21.9%and 59.1%, respectively.Compare to the group of non-drug,there was no significant difference to the group of 1μg/L TRAIL(P＞0.05),whereas there was a significant difference to the group 10,100μg/L TRAIL(P＜0.01).10.0mg/L MMC on bladder cancer T24,5637 cell strains, the GIR were 36.0%,26.7%,whereas 100μg/L TRAIL combined with 10.0mg/L MMC on the bladder tumor cell strains T24,5637,the GIR reached 58.4%,90.7%,respectively, There was significant difference to 100μg/L TRAIL and 10.0mg/L MMC,both have obvious synergy(P＜0.05).②the results of detecting by flow cytometry:100μg/L TRAIL induced bladder tumor cell strains T24,5637 apoptosis,apoptosis rates were 20.1%,47.5%, and there was a significant differences(P＜0.01) to the apoptosis rate 1.9%,5.1%of the group of non-drug;The apoptosis rates were 13.1%,18.1%,respectively.when use individually 10.0mg/L MMC on bladder cancer cell strains T24,5637;whereas 100μg/L TRAIL combined with 10.0mg/L MMC on the bladder tumor cell strains T24,5637,the apoptosis rate reached 41.5%,61.5%,respectively.There was significant difference to 100μg/L TRAIL and 10.0mg/L MMC,both have obvious synergy in two cell strains (p＜0.05).
Conclusions:In vitro,①TRAIL can effectively inhibit the growth of bladder cancer cell strains T24,5637,and it also can induce apoptosis in human bladder tumor cell strains T24,5637.②TRAIL can enhance the effect of MMC on inhibiting the growth of human bladder cancer cell strains T24,5637,and they also have the synergistic effect on induction of human bladder cancer cell strains apoptosis.
PartⅡThe effect of Ad-TRAIL and MMC on bladder tumors in vivo
Objective:To study the therapeutic effects of eukaryotic expression vector coding human tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) combined with Mitomycin C(MMC) on bladder carcinoma in vivo.
Methods:Methods:①T24 human bladder cancer cell strain cultivate in vitro.Five 6-week-old immune-deficient mice(BALB/c-nu),the roots of the right forelimb dorsal skin with 75%alcohol disinfection,then inoculated subcutaneously with 0.2ml concentration of 1×10~7/ml of the T24 human bladder cancer cell line suspension.Up to the tumor size of 1cm in diameter,the mice were sacrificed and tumors excised,check the texture uniformity of department organizations,and cut into about 2 mm~3,10～15mg size, 40 mice of 6-week-old BALB/c-nu were transplanted to subcutaneous dorsal roots of the right forelimb.Transplantation methods:using 75%alcohol disinfection of transplanted skin,cut the size of 0.4cm skin incision,separation of subcutaneous tissue,the subcutaneous tissue implants,0~# suture the skin incision line.Continue to conventional feeding mice and to observe changes in the injection site.②These 40 BALB/c-nu mice, tumor grow to 0.4～0.6cm were randomly divided into four groups,namely group MMC(A group):intraperitoneal injection of 0.1g/L MMC(10μl/g body weight) keep on 7d; intratumoral injection of 5×10~8 pfu/ml Ad empty vector 0.1ml×3,the tumors were injected in 4,8,12 points,1/2d,a total of 3 times;Group Ad-TRAIL(B group):abdominal injection of PB S(10μl/g)×7d,intratumoral injection of 5×10~8 pfu/ml Ad-TRAIL 0.1ml×3, 1/2d,a total of 3 times;Group MMC and Ad-TRAIL(C group):abdominal injection of MMC as the group A,intratumoral injection of Ad-TRAIL as the group B;group control (group D):intraperitoneal injection of PBS(10μl/g)×7d,intratumoral injection of 5×10~8 pfu/ml Ad empty vector 0.1ml×3 sites,1/2d,a total of 3 times.Two weeks after drug delivery,to measure mouse body weight,diameter and weight of tumors,observe the tumor cells under the microscope(×400),and measure the TRAIL mRNA and TRAIL protein expression within tumor tissue by using RT-PCR and western blot.
Results:①the first batch of five mice,has three tumor-bearing model of success,to cells after injection of 50d,3 tumor-beating mice diameter reach 0.6～1.0cm,and confirmed by histopathology;the second batch of 40 mice tumor model for all of the success of tumor rate was 100%,4 weeks after transplantation all mice tumor diameter are 0.4～0.6cm.②pre-delivery weight and the load average diameter of the tumor was no significant difference in four groups of mice(P＞0.05);Tumor diameter and weight of group A,B,C were significantly smaller than group D(P＜0.001)2 weeks after delivery, while the group C was significantly smaller than group A and B(P＜0.01),group B was significantly smaller than group A(P＜0.001);Weight of group A and C were significantly less than group D(P＜0.01),while there was no significant difference between group B and group D(P＞0.05);Under the microscope,the necrosis of tumor cells, group C＞B＞A＞D;TRAIL mRNA and TRAIL protein expressed in tumor cell within Group B and C,and the difference of expression of the relative volume of Group B and C was not statistically significance(P＞0.05),while group A and D did not express the TRAIL mRNA and TRAIL protein in tumor cells.
Conclusion:①Constructed successfully in nude mice of human bladder cancer cell strain T24 nude model;②Experiments in vivo,Ad-TRAIL was successful transfected into T24 bladder cancer and expressed TRAIL protein;③MMC and Ad-TRAIL have obvious inhibitory effect to T24 human bladder cancer in nude mice transplanted tumor,and both has synergistic effect with combination.
引文
1 Parkin MD,Bray F,Ferlay J,et al.Global Cancer Statistics,2002.CA Cancer J Clin,2005,55(2):74-108.
2 Jemal A,Siegel R,Ward E,et al.Cancer Statistics,2006.CA Cancer J Clin,2006,56:106-130.
3 虞颂庭,臧美孚,夏溟。尿路上皮肿瘤概论。见:吴阶平。吴阶平泌尿外科学,济南:山东科学技术出版社,2004.919-942.
4 Lipponen P,Eskelinen M,Syrjanen S,et al.Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder.Eur Urol,1991,20(3):238-242.
5 Fontana D,Bellina M,Scoffone C,et al.Evaluation of c-ras oncogene product(p21)in superficial bladder cancer.Eur Urol,1996,29(4):470-476.
6 邵渊,张元芳,陆洪芬,等。C-erb B2、H-ras和p53、Rb基因在膀胱癌中的表达。中华泌尿外科杂志,1997,18(4):215-218.
7 Pollack A,Wu CS,Czemiak B,et al.Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.Clin Cancer Res,1997,3:1823-1829.
8 柳建军,曹军,苏劲,等。p53、c-erbB2和bcl-2基因在膀胱癌中的表达及意义。临床泌尿外科杂志,2001,16(8):368-370.
9 何杰,汪万英、朱应葆,等。p16和bcl-2基因在膀胱癌中的表达及意义。肿瘤学杂志,2001,7(2):81-83.
10 Van Rhijn BW,Lurkin I,Radvanyi F,et al.The fibroblast growth factor receptor 3(FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.Cancer Res,2001,61:1265-1268.
11 Lipponen PK.Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.J Pathol,1995,175(2):203-210.
12 Schmitz Drager BJ,Schulz WA,Jurgens B,et al.C-myc in bladder cancer.Clinical findings and analysis of mechanism.Urol Res,1997,25(suppl 1):S45-S49.
13 Gorgoulis VG,Barbatis C,Poulias I,et al.Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder:a study in Greek patients.Mod Pathol,1995,8(7):758-764.
14 Moriyama M,Akiyama T,Yamamoto T,et al.Expression of c-erbB-2 gene product in urinary bladder cancer.J Urol,1991,145(2):423-427.
15 李和程,石涛,王子明。p53和MDM2基因表达及与膀胱癌生物学行为的关系。临床泌尿外科杂志,2001,16(12):526-528.
16 Montie JE.CDC91L1(PIG-U)is a newly discovered oncogene in human bladder cancer.J Urol,2005,174(3):869-870.
17 Williams SG,and Stein JP.Molecular pathways in bladder cancer.Urol Res,2004,32(6):373-385.
18 Cordon-Cardo C,Wartinger D,Petrylak D,et al.Altered expression of the retinoblastoma gene product:prognostic indicator in bladder cancer.J Natl Cancer Inst,1992,84(16):1251-1256.
19 Grossman HB,Liebert M,Antelo M,et al.p53 and Rb expression predict progression in T_1 bladder cancer.Clin Cancer Res,1998,4:829-834
20 Waters WB.Invasive bladder cancer-where do we go from here? J Urol,1996,155(6):1910-1911.
21 Tolley DA,Parmar MK,Grigor KM,et al.The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer:a further report with 7 years of follow up.J Urol,1996,155(4):1233-1238.
22 Sylvester RJ,van der Meijden AP,Oosterlinck W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials.Eur Urol,2006,49(3):466-477.
23 Nseyo UO,Lamm DL.Therapy of superficial bladder cancer.Semin Oncol 1996;23(5):598-604.
24 Jakse G,Algaba F,Fossa S,et al.EAU Guidelines on bladder cancer muscle-invasive and metastatic.March 2004.
25 Wiley SR,Schooley K,Smolak PJ,et al.Identification and characterization of a new member of the TNF family that induces apoptosis.Immubity,1995,3(6):673-682.
26 Kim Y,Seol DW.TRAIL,a mighty apoptosis inducer.Mol Cells,2003,15(3):283-293.
27 Gliniak B,Le T.Tumor necrosis factor-ralated apoptosis- inducing ligand's antitumor activity in vivo is enchanced by the chemotherapeutic agent CPT-11.Cancer Res 1999,59:6153-6158.
28 Nagane M,Pan G,Weddle JJ,et al.Increased death receptor 5 expression by Chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor- related apoptosis-inducing liangd in vitro and in vivo.Cancer Res 2000,60:847-853.
29 Mizutani Y,Nakao M,Ogawa O,et al.Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.J Urol 2001,165(1):263-270.
30 张志超,张智清,张强,等。TRAIL受体在膀胱癌中的表达及意义。中华泌尿外科杂志,2001,22(10):616-618.
1 Wiley SR,Schooley K,Smolak PJ,et al.Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity,1995,3(6):673-682.
2 Pitti RM,Marsters SA,Ruppert S.et al.Induction of apoptosis by Apo-2 ligand,a new member of the tumor necrosis factor cytokine family.J Biol Chem,1996 May 31;271(22):12687-12690.
3 Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol,1999,11(2):255-260.
4 riffith TS, Chin WA, Jackson GC, et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.J Immunol, 1998, 161(6): 2833-2840.
5 Gura T, How TRAIL kills cancer cells, but not normal cells. Science, 1997, 277 (5327):768-770.
6 Trabzuni D, Famulski KS, Ahmad M. Functional analysis of tumour necrosis factor related apoptosis inducing ligand(TRAIL):cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J,2000,350(pt2):505-510.
7 Seol DW, Billiar TR. Cysteine 230 modulates tumor necrosis factor-related apoptosis inducing-Iigand activity. Cancer Res,2000,60(12):3152-3154.
8 Hymowitz SG, O'Connell MP, Ultsch MH, et al. A unique zine-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry,2000, 39(4):633-640.
9 Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer. Mol Cells, 2003,15(3): 283-293.
10 Pan GO, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science, 1997,276(5309): 111-113.
11 Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science,1997,277(5327):818-821.
12 Chaudhary PM, Eby M, Jasmin A, et al. Death receptor 5,a new member of the TNFR family,and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity, 1997,7(6):821 -830.
13 Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science,1997,277(5327):815-818.
14 Schneider P, Thome M, Burns K, et al. TRAIL receptor 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB, Immurity 1997; 7 (6):831-836.
15 Emery JG, McDonnell P, Burke MB, et al. Osteoprotogerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem,1998,273:14363-14367.
16 Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med,1997,186(7): 1165-1170.
17 Bratton SB, MacFarlane M, Cain K, et al. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res, 2000, 256(1) :27-33.
18 Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts:inhibition by Bcl-2 and repuirement for an organelle fraction enriched in mitochondria. Cell 1994,79(2):353-364.
19 Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 1996,86(1):147-157.
20 Wajant H, Haas E, Schwenzer R, et al. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein(FADD). J Biol Chem, 2000, 275(32): 24357-24366.
21 Ishiguro K, Ando T, Maeda O, et al. Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun, 2007, 362 (1):218-223.
22 G, Ni J, WeiY F ,et al .An antagonist decoy receptor and a death domain-Containing receptor for TRAIL. Science,1997,277(5327):815-818.
23 Kaplan D,Sieg S .Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease. J Virol,1998;72(8):6279-6282.
24 Hassen W, Droller MJ. Current concepts in assessment and treatment of bladder cancer.Curr Opin Urol, 2000, 10(4): 291-299.
25 Dreicer R, Kollomergen TA, Smith RF, et al. Neoadjuvant cisplatin, methotrexate, and vinblastine for muscle-invasive bladder cancer: long term follow-up. J Urol, 1993; 150(3): 849-852.
26 吴长利,张文岚,畅继武,等.MDR1/P-gp在膀胱移行细胞癌中的表达及与Fas和Survivin蛋白表达的关系.中国肿瘤临床,2007,34(2):82-85.
27 王平,董德平,陆连英,等.p53过度表达与膀胱癌预后关系的初步探讨.中华泌尿外科杂志,1999,20(7):27-28.
28 张江兰,陈秀玲,薄爱华,等.DNA拓扑异构酶Ⅱ在膀胱癌中表达的临床意义.河北北方学院学报,2005,22(3):14-15.
29 Cuello M,Ettenberg SA,Nau MM,et al.Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells.Gynecol Oncol,2001,81(3):380-390.
30 赵旭,陈孝平,何宋青,等.TRAIL联合阿霉素诱导肝癌耐药株凋亡的实验研究.消化外科,2005,4(3):202-207.
31 Mizutani Y,Nakao M,Ogawa O,et al.Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.J Urol 2001,165(1):263-270.
32 Gliniak B,Le T.Tumor necrosis factor-ralated apoptosis- inducing ligand's antitumor activity in vivo is enchanced by the chemotherapeutic agent CPT-11.Cancer Res,1999,59:6153-6158.
1 高进.免疫缺陷动物在肿瘤细胞侵袭研究中的应用.北京实验动物科学,1992,9(4):1-4.
2 Xia D J,Zhang WP,Zheng S,et al.Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.Gene Ther.2002 May;9(9):592-601.
3 Sun FX,Tang ZY,Lui KD,et al.Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues.Int J Cancer,1996,66(2):239-243.
4 James G,Rheinwald,Michael A,et al.Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas.Cancer Res,1981,41:1657-1663.
5 Fidler IJ.Critical factors in the biology of human cancer metastasis:Twenty-eighth G.H.A.Clowes memorial award lecture.Cancer Res.1990;50:6130-6138.
6 方喜业,主编.医学实验动物学.北京:人民卫生出版社.1995:193.
7 Hamilton TC,Young RC,Louie KG,et al.Characterization of a xenografl model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.Cancer Res.1984;44:5286-5290.
8 陈陵际.运用人癌裸小鼠种植瘤模型进行抗癌新药评价.上海实验动物科学,2001,21(4):247-250.
9 Yamamoto C,Takemoto H,Kuno K,et al.Cycloprodigiosin hydrochloride,a new H(+)/Cl(-) symporter,induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografis in nude mice.Hepatology,1999,30(4):894-902.
10 Smith MJ,Takeda K,Hayakawa Y,et al.Nature's TRAIL-on a Path to Cancer Immunotherapy.Immunity,2003,18(1):1-6.
11 张仲宁,喻爱喜,侯炜,等.肿瘤坏死因子相关诱导凋亡配体联合阿霉素治疗骨肉瘤.中华实验外科杂志,2006,23(2):141-143.
12 沈瑞林,金晓东,沈周俊,等.肿瘤坏死因子相关诱导凋亡配体联合化疗药物治疗膀胱癌的研究.中华实验外科杂志,2003,20(9):840-842.
13 沈瑞林,温端改,侯健全,等.真核表达载体Ad-hTRAIL联合丝裂霉素治疗膀胱癌.中华实验外科杂志,2008,25(11):1475-1478.
14 Gliniak B,Le T.Tumor necrosis factor-related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.Cancer Res,1999,59:6153-6158.
15 Walczak H,Miller RE,Ariail K,et al.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.Nat.med,1999,5(2):157-163.
16 Nakamura M,Rieger J,Weller M,et al.APO2L/TRAIL expression in human brain tumors.Acta Neuropathol,2000,99(1):1-6.
17 Rieger J,Ohgaki H,Kleihues P,et al.Human astrocytic brain tumors express APO2L/TRAIL.Acta Neuropathol,1999,97(1):1-4.
18 Roth W,Isenmann S,Naumann U,et al.Locoregional Apo2L/TRAIL eradicates intracranial human malignant gioma xenografts in athymic mice in the absence of neurotoxi city.Biochem Biophys Res Commun,1999,265(2):479-483.
19 Ashkenazi A,Pai RC,Fong S,et al.Safety and antitumor activity of recombinant solube Apo2 ligand.J Clin Invest,1999,104(2):155-162.
20 Jazirehi AR, Ng CP, Gan XH, et al. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated(TRAIL) apoptosis. Clin Cancer Res, 2001, 7:3874-3883.
21 Mizutani Y, Nakanishi H, Yoshida 0, et al. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer, 2002,38(1): 167-176.
22 Spalding AC, Jotte RM, Scheinman RI, et al. TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene.2002,21(2):260-271.
23 Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res.2001,61(4): 1645-1651.
24 Mitsiades N, Mitsiades CS, Poulaki V, et al. Concepts in the use of TRAIL/ Apo2L:an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs.2001,10(8):1521-1530.
25 Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.Cancer Res, 2000,60:847-853.
26 Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.Prostate, 2005, 62(2): 165-186.
27 Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther,2007, 6: 1387-1399.
1 吴在德.外科学.北京:人民卫生出版社,2000,76.
2 Pow-Sang JM,Seigne JD.Contemporary management of superficial bladder cancer.Cancer Control,2000,7(4):335-339.
3 Waters WB.Invasive bladder cancer-where do we go from here? J Urol,1996,155(6):1910-1911.
4 Tolley DA,Parmar MK,Grigor KM,et al.The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer:a further report with 7 years of follow up.J Urol,1996,155(4):1233-1238.
5 Sylvester RJ, van der Meijden AP,Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006,49(3): 466-477.
6 Boyar M,Petrylak DP.Adjuvant chemotherapy for transitional cell carcinoma of the bladder:paradigms for the design of clinical trails. Curr Oncol Rep. 2005 May; 7(3):207-214.
7 York A. Gene therapy: the state of the art. Lancet Oncol. 2005; 6(4): 196-202.
8 Kuriyamas S, Tsujinoue H,Yoshiji H. Immune response to suicide gene therapy.Methods Mol Med. 2004;90:353-369.
9 Gough M, Crittenden M, Thanarajasingam U, et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol. 2005; 174: 5766-5773.
10 Kawakami K. Cancer Gene Therapy Utilizing Interleukin-13 Receptor alpha2 Chain. Curr Gene Ther. 2005;5(2):213-223.
11 Fujii H, Inobe M, Kimura F, et al. Vaccination of tumor cells transfected with the B7-1(CD 80 ) gene induces the antimetastatic effect and tumor immunity in mice.Int J Cancer, 1996,66(2):219-224.
12 Baskar S, Glimcher L, Nabavi N, et al. Major histocompatibility complex class II~+B7-1~+tumor cells are potent vaccines for stimulating tumor rejection in tumor -bearing mice. J Exp Med,1995,181:619-629.
13 Connor J,Bannerji R,Saito S, et al. Regression of bladder tumors in mice treated with interleukin-2 gene modified tumor cells. J Exp Med,1993,177:1127-1134.
14 Horiguchi Y ,Larchian WA,Kaplinsky R,et al. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther,2000,7:844-851.
15 Grote HJ, Schmiemann V, Geddert H, et al. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer.Int J Cancer. 2005; 116(5):720-725.
16 McNeish IA,Bell SJ,Lemoine NR.Gene therapy progress and prospects:cancer gene therapy using tumour suppressor genes.Gene Ther,2004,11(6):497-503.
17 Fodor I,Timiryasova T,Denes B,et al.Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model.J Urol,2005;173(2):604-609.
18 Irie A,Uchida T,Ishida H,et al.p53 Mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells.Mol Uorl,2001,5(2):53-58.
19 Wada Y,Gotoh A,Shirakawa T,et al.Gene therapy for bladder cancer using adenoviral vector.Mol Urol,2001,5(2):47-52.
20 Pagliaro LC.Gene therapy for bladder cancer.World J Urol,2000,18(2):148-151.
21 Xu HJ,Zhou Y,Seigne J,et al.Enhanced tumor suppressor genetherapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein.Cancer Res,1996,56(10):2245-2249.
22 Takino H,Okabe M,Li C,et al.p16/INK4a gene methylation is a frequent finding in pulmonary MALT lymphomas at diagnosis.Mod Pathol.2005;18:1187-1192.
23 GrimJ,D'Amico A,Frizelle S,et al.Adenovirus-mediated delivery of p16 to p16-deficient Human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.Clin Cancer Res,1997,3(12):2415-2423.
24 张海江,王楠,朱晓宇,等.增强p52、p21及抑制c-myc表达对MCF-7细胞增殖的协同抑制作用.实验生物学报,2005;38(1):16-22.
25 Glazko GV,Babenko VN,Koonin EV,et al.Mutational hotspots in the TP53 gene and,possibly,other tumor suppressors evolve by positive selection.Biol Direct,2006,1:4-13.
26 Cairns P,Evron E,Okami K,et al.Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.Oncogene,1998,16:3215-3218.
27 Irie A,Anderegg B,Kashani Sabet M,et al.Therapeutic efficacy of an adenovirusmediated ant-H-ras ribozyme in experimental bladder cancer.Antisense Nucleic Acid Drug Dev,1999,9(4):341-349.
28 Irie A,Kashani-Sabet M,Scanlon KJ,et al.Hammerhead ribozymes as therapeutic agents for bladder cancer. Mol Urol,2000,4(2):61-66.
29 Unfer RC,Hellrung D,Link CJ,et al. Immunity to the alpha(l,3) galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3) galactosyl-transferase: a novel suicide gene for cancer gene therapy, Cancer Res, 2003,63:987-993.
30 Mazzolini G,Prieto J,Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des,2003,9(24):1981-1991.
31 Chan RC,Pang XW,Wang YD,et al. Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells. Br J Cancer,2004,90(8):1636-1463.
32 Larchian WA, Horiguchi Y,Nair SK,et al. Effectiveness of combined interleukin 2 and B7. 1 vaccination strategy is dependent on the sequence and order: a liposome mediaetd gene therapy treatment for blader cancer. Clin Cancer Res, 2000, 6: 2913-2920.
33 Genega EM,Hutchinson B,Reuter VE,et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma .Mod Pathol, 2000, 13(11): 1186-1191.
34 Zhu M Z,Marshall J,Cole D,et al. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res,2000,6 :24-33.
35 Finocchiaro LM,Bumascliny VF,Karara AL,et al. Herpes simplex virus thymidine kinase/ ganciclovir system in multicellular tumor spheroids. Cancer Gene Ther, 2004,11(5) :333-345.
36 Wang Z,Cook T,Alber S,et al. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vasculairty. Cancer Res, 2004,46: 1386-1395.
37 Akasaka S,Suzuki S,Shimizu H,et al. Suicide gene therapy for chemically induced rat bladder tumor entailing instillation of adenoviral vectors. Jpn J Cancer Res, 2001, 92 (5):568 -575.
38 Freund CT,Tong XW,Block A,et al.Adenovirus-mediated suicide gene therapy for bladder cancer:comparison of the cytomegalovirus and Rous sarcoma virus promoter.AnticancerRes,2000,20(5A):2811-2816.
39 Matono S,Tanaka T,Sueyoshi S,et al.Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer.Int J Oncol.2003;23(5):1309-1315.
40 Tanaka M,Fraizer GC,De La Cerda J,et al.Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery.Gene Ther,2001,8:139-148.
41 Walther W,Wendt J,Stein U.Employment of the mdrl promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy.Gene Ther,1997,4:544-552.
42 Griffith TS,Anderson RD,Davidson BL,et al.Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis.J Immunol,2000,165:2886-2894.
43 沈瑞林,金晓东,沈周俊,等.肿瘤坏死因子相关诱导凋亡配体联合化疗药物治疗膀胱癌的研究.中华实验外科杂志,2003,20(9):840-842.
44 沈瑞林,温端改,侯健全,等.真核表达载体Ad-hTRAIL联合丝裂霉素治疗膀胱癌.中华实验外科杂志,2008,25(11):1475-1478.
45 Mizutani Y,Nakao M,Ogawa O,et al.Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.J Urol,2001,165(1):263-270.
46 Oshima Y,Takahashi K,Oshima S,et al.Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization.J Cell Physiol.2004;199(3):399-411.
47 Stilwell JL,McCarty DM,Negishi A,et al.Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.J Virol.2003; 77(23):12881-12885.
48 Xiao W,Chirmule N,Schnell MA,et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther,2000,1:323-329.
49 Naka K, Tachibana A, Ikeda K, et al. Stress-induced premature sensescence in hTERT-expressing ataxia telangiectasia fibroblasts. J Biol chem. 2004, 279(3): 2030-2037.
50 Kraemer K, Fuessel S, Schmidt U, et al.Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res. 2003,9:3794-3800.
51 Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer,1997,33(5):787-791.
52 Nakamura T, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science,1997.277(5328):955-959.
53 Meyerson M, Counter CM, Eaton EN, et al. hEST2,The putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.cell,1977,90(4):785-795.
54 Tahara H, Tahara E, Ide T. Telomere and telomerase associated genes.Gan to kagaku Ryoho,1997,24(15):2196-2201.
2 Jemal A,Siegel R,Ward E,et al.Cancer Statistics,2006.CA Cancer J Clin,2006,56:106-130.
3 虞颂庭,臧美孚,夏溟。尿路上皮肿瘤概论。见:吴阶平。吴阶平泌尿外科学,济南:山东科学技术出版社,2004.919-942.
4 Lipponen P,Eskelinen M,Syrjanen S,et al.Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder.Eur Urol,1991,20(3):238-242.
5 Fontana D,Bellina M,Scoffone C,et al.Evaluation of c-ras oncogene product(p21)in superficial bladder cancer.Eur Urol,1996,29(4):470-476.
6 邵渊,张元芳,陆洪芬,等。C-erb B2、H-ras和p53、Rb基因在膀胱癌中的表达。中华泌尿外科杂志,1997,18(4):215-218.
7 Pollack A,Wu CS,Czemiak B,et al.Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.Clin Cancer Res,1997,3:1823-1829.
8 柳建军,曹军,苏劲,等。p53、c-erbB2和bcl-2基因在膀胱癌中的表达及意义。临床泌尿外科杂志,2001,16(8):368-370.
9 何杰,汪万英、朱应葆,等。p16和bcl-2基因在膀胱癌中的表达及意义。肿瘤学杂志,2001,7(2):81-83.
10 Van Rhijn BW,Lurkin I,Radvanyi F,et al.The fibroblast growth factor receptor 3(FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.Cancer Res,2001,61:1265-1268.
11 Lipponen PK.Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.J Pathol,1995,175(2):203-210.
12 Schmitz Drager BJ,Schulz WA,Jurgens B,et al.C-myc in bladder cancer.Clinical findings and analysis of mechanism.Urol Res,1997,25(suppl 1):S45-S49.
13 Gorgoulis VG,Barbatis C,Poulias I,et al.Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder:a study in Greek patients.Mod Pathol,1995,8(7):758-764.
14 Moriyama M,Akiyama T,Yamamoto T,et al.Expression of c-erbB-2 gene product in urinary bladder cancer.J Urol,1991,145(2):423-427.
15 李和程,石涛,王子明。p53和MDM2基因表达及与膀胱癌生物学行为的关系。临床泌尿外科杂志,2001,16(12):526-528.
16 Montie JE.CDC91L1(PIG-U)is a newly discovered oncogene in human bladder cancer.J Urol,2005,174(3):869-870.
17 Williams SG,and Stein JP.Molecular pathways in bladder cancer.Urol Res,2004,32(6):373-385.
18 Cordon-Cardo C,Wartinger D,Petrylak D,et al.Altered expression of the retinoblastoma gene product:prognostic indicator in bladder cancer.J Natl Cancer Inst,1992,84(16):1251-1256.
19 Grossman HB,Liebert M,Antelo M,et al.p53 and Rb expression predict progression in T_1 bladder cancer.Clin Cancer Res,1998,4:829-834
20 Waters WB.Invasive bladder cancer-where do we go from here? J Urol,1996,155(6):1910-1911.
21 Tolley DA,Parmar MK,Grigor KM,et al.The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer:a further report with 7 years of follow up.J Urol,1996,155(4):1233-1238.
22 Sylvester RJ,van der Meijden AP,Oosterlinck W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials.Eur Urol,2006,49(3):466-477.
23 Nseyo UO,Lamm DL.Therapy of superficial bladder cancer.Semin Oncol 1996;23(5):598-604.
24 Jakse G,Algaba F,Fossa S,et al.EAU Guidelines on bladder cancer muscle-invasive and metastatic.March 2004.
25 Wiley SR,Schooley K,Smolak PJ,et al.Identification and characterization of a new member of the TNF family that induces apoptosis.Immubity,1995,3(6):673-682.
26 Kim Y,Seol DW.TRAIL,a mighty apoptosis inducer.Mol Cells,2003,15(3):283-293.
27 Gliniak B,Le T.Tumor necrosis factor-ralated apoptosis- inducing ligand's antitumor activity in vivo is enchanced by the chemotherapeutic agent CPT-11.Cancer Res 1999,59:6153-6158.
28 Nagane M,Pan G,Weddle JJ,et al.Increased death receptor 5 expression by Chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor- related apoptosis-inducing liangd in vitro and in vivo.Cancer Res 2000,60:847-853.
29 Mizutani Y,Nakao M,Ogawa O,et al.Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.J Urol 2001,165(1):263-270.
30 张志超,张智清,张强,等。TRAIL受体在膀胱癌中的表达及意义。中华泌尿外科杂志,2001,22(10):616-618.
1 Wiley SR,Schooley K,Smolak PJ,et al.Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity,1995,3(6):673-682.
2 Pitti RM,Marsters SA,Ruppert S.et al.Induction of apoptosis by Apo-2 ligand,a new member of the tumor necrosis factor cytokine family.J Biol Chem,1996 May 31;271(22):12687-12690.
3 Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol,1999,11(2):255-260.
4 riffith TS, Chin WA, Jackson GC, et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.J Immunol, 1998, 161(6): 2833-2840.
5 Gura T, How TRAIL kills cancer cells, but not normal cells. Science, 1997, 277 (5327):768-770.
6 Trabzuni D, Famulski KS, Ahmad M. Functional analysis of tumour necrosis factor related apoptosis inducing ligand(TRAIL):cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J,2000,350(pt2):505-510.
7 Seol DW, Billiar TR. Cysteine 230 modulates tumor necrosis factor-related apoptosis inducing-Iigand activity. Cancer Res,2000,60(12):3152-3154.
8 Hymowitz SG, O'Connell MP, Ultsch MH, et al. A unique zine-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry,2000, 39(4):633-640.
9 Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer. Mol Cells, 2003,15(3): 283-293.
10 Pan GO, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science, 1997,276(5309): 111-113.
11 Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science,1997,277(5327):818-821.
12 Chaudhary PM, Eby M, Jasmin A, et al. Death receptor 5,a new member of the TNFR family,and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity, 1997,7(6):821 -830.
13 Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science,1997,277(5327):815-818.
14 Schneider P, Thome M, Burns K, et al. TRAIL receptor 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB, Immurity 1997; 7 (6):831-836.
15 Emery JG, McDonnell P, Burke MB, et al. Osteoprotogerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem,1998,273:14363-14367.
16 Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med,1997,186(7): 1165-1170.
17 Bratton SB, MacFarlane M, Cain K, et al. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res, 2000, 256(1) :27-33.
18 Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts:inhibition by Bcl-2 and repuirement for an organelle fraction enriched in mitochondria. Cell 1994,79(2):353-364.
19 Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 1996,86(1):147-157.
20 Wajant H, Haas E, Schwenzer R, et al. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein(FADD). J Biol Chem, 2000, 275(32): 24357-24366.
21 Ishiguro K, Ando T, Maeda O, et al. Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun, 2007, 362 (1):218-223.
22 G, Ni J, WeiY F ,et al .An antagonist decoy receptor and a death domain-Containing receptor for TRAIL. Science,1997,277(5327):815-818.
23 Kaplan D,Sieg S .Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease. J Virol,1998;72(8):6279-6282.
24 Hassen W, Droller MJ. Current concepts in assessment and treatment of bladder cancer.Curr Opin Urol, 2000, 10(4): 291-299.
25 Dreicer R, Kollomergen TA, Smith RF, et al. Neoadjuvant cisplatin, methotrexate, and vinblastine for muscle-invasive bladder cancer: long term follow-up. J Urol, 1993; 150(3): 849-852.
26 吴长利,张文岚,畅继武,等.MDR1/P-gp在膀胱移行细胞癌中的表达及与Fas和Survivin蛋白表达的关系.中国肿瘤临床,2007,34(2):82-85.
27 王平,董德平,陆连英,等.p53过度表达与膀胱癌预后关系的初步探讨.中华泌尿外科杂志,1999,20(7):27-28.
28 张江兰,陈秀玲,薄爱华,等.DNA拓扑异构酶Ⅱ在膀胱癌中表达的临床意义.河北北方学院学报,2005,22(3):14-15.
29 Cuello M,Ettenberg SA,Nau MM,et al.Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells.Gynecol Oncol,2001,81(3):380-390.
30 赵旭,陈孝平,何宋青,等.TRAIL联合阿霉素诱导肝癌耐药株凋亡的实验研究.消化外科,2005,4(3):202-207.
31 Mizutani Y,Nakao M,Ogawa O,et al.Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.J Urol 2001,165(1):263-270.
32 Gliniak B,Le T.Tumor necrosis factor-ralated apoptosis- inducing ligand's antitumor activity in vivo is enchanced by the chemotherapeutic agent CPT-11.Cancer Res,1999,59:6153-6158.
1 高进.免疫缺陷动物在肿瘤细胞侵袭研究中的应用.北京实验动物科学,1992,9(4):1-4.
2 Xia D J,Zhang WP,Zheng S,et al.Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.Gene Ther.2002 May;9(9):592-601.
3 Sun FX,Tang ZY,Lui KD,et al.Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues.Int J Cancer,1996,66(2):239-243.
4 James G,Rheinwald,Michael A,et al.Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas.Cancer Res,1981,41:1657-1663.
5 Fidler IJ.Critical factors in the biology of human cancer metastasis:Twenty-eighth G.H.A.Clowes memorial award lecture.Cancer Res.1990;50:6130-6138.
6 方喜业,主编.医学实验动物学.北京:人民卫生出版社.1995:193.
7 Hamilton TC,Young RC,Louie KG,et al.Characterization of a xenografl model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.Cancer Res.1984;44:5286-5290.
8 陈陵际.运用人癌裸小鼠种植瘤模型进行抗癌新药评价.上海实验动物科学,2001,21(4):247-250.
9 Yamamoto C,Takemoto H,Kuno K,et al.Cycloprodigiosin hydrochloride,a new H(+)/Cl(-) symporter,induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografis in nude mice.Hepatology,1999,30(4):894-902.
10 Smith MJ,Takeda K,Hayakawa Y,et al.Nature's TRAIL-on a Path to Cancer Immunotherapy.Immunity,2003,18(1):1-6.
11 张仲宁,喻爱喜,侯炜,等.肿瘤坏死因子相关诱导凋亡配体联合阿霉素治疗骨肉瘤.中华实验外科杂志,2006,23(2):141-143.
12 沈瑞林,金晓东,沈周俊,等.肿瘤坏死因子相关诱导凋亡配体联合化疗药物治疗膀胱癌的研究.中华实验外科杂志,2003,20(9):840-842.
13 沈瑞林,温端改,侯健全,等.真核表达载体Ad-hTRAIL联合丝裂霉素治疗膀胱癌.中华实验外科杂志,2008,25(11):1475-1478.
14 Gliniak B,Le T.Tumor necrosis factor-related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.Cancer Res,1999,59:6153-6158.
15 Walczak H,Miller RE,Ariail K,et al.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.Nat.med,1999,5(2):157-163.
16 Nakamura M,Rieger J,Weller M,et al.APO2L/TRAIL expression in human brain tumors.Acta Neuropathol,2000,99(1):1-6.
17 Rieger J,Ohgaki H,Kleihues P,et al.Human astrocytic brain tumors express APO2L/TRAIL.Acta Neuropathol,1999,97(1):1-4.
18 Roth W,Isenmann S,Naumann U,et al.Locoregional Apo2L/TRAIL eradicates intracranial human malignant gioma xenografts in athymic mice in the absence of neurotoxi city.Biochem Biophys Res Commun,1999,265(2):479-483.
19 Ashkenazi A,Pai RC,Fong S,et al.Safety and antitumor activity of recombinant solube Apo2 ligand.J Clin Invest,1999,104(2):155-162.
20 Jazirehi AR, Ng CP, Gan XH, et al. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated(TRAIL) apoptosis. Clin Cancer Res, 2001, 7:3874-3883.
21 Mizutani Y, Nakanishi H, Yoshida 0, et al. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer, 2002,38(1): 167-176.
22 Spalding AC, Jotte RM, Scheinman RI, et al. TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene.2002,21(2):260-271.
23 Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res.2001,61(4): 1645-1651.
24 Mitsiades N, Mitsiades CS, Poulaki V, et al. Concepts in the use of TRAIL/ Apo2L:an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs.2001,10(8):1521-1530.
25 Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.Cancer Res, 2000,60:847-853.
26 Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.Prostate, 2005, 62(2): 165-186.
27 Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther,2007, 6: 1387-1399.
1 吴在德.外科学.北京:人民卫生出版社,2000,76.
2 Pow-Sang JM,Seigne JD.Contemporary management of superficial bladder cancer.Cancer Control,2000,7(4):335-339.
3 Waters WB.Invasive bladder cancer-where do we go from here? J Urol,1996,155(6):1910-1911.
4 Tolley DA,Parmar MK,Grigor KM,et al.The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer:a further report with 7 years of follow up.J Urol,1996,155(4):1233-1238.
5 Sylvester RJ, van der Meijden AP,Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006,49(3): 466-477.
6 Boyar M,Petrylak DP.Adjuvant chemotherapy for transitional cell carcinoma of the bladder:paradigms for the design of clinical trails. Curr Oncol Rep. 2005 May; 7(3):207-214.
7 York A. Gene therapy: the state of the art. Lancet Oncol. 2005; 6(4): 196-202.
8 Kuriyamas S, Tsujinoue H,Yoshiji H. Immune response to suicide gene therapy.Methods Mol Med. 2004;90:353-369.
9 Gough M, Crittenden M, Thanarajasingam U, et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol. 2005; 174: 5766-5773.
10 Kawakami K. Cancer Gene Therapy Utilizing Interleukin-13 Receptor alpha2 Chain. Curr Gene Ther. 2005;5(2):213-223.
11 Fujii H, Inobe M, Kimura F, et al. Vaccination of tumor cells transfected with the B7-1(CD 80 ) gene induces the antimetastatic effect and tumor immunity in mice.Int J Cancer, 1996,66(2):219-224.
12 Baskar S, Glimcher L, Nabavi N, et al. Major histocompatibility complex class II~+B7-1~+tumor cells are potent vaccines for stimulating tumor rejection in tumor -bearing mice. J Exp Med,1995,181:619-629.
13 Connor J,Bannerji R,Saito S, et al. Regression of bladder tumors in mice treated with interleukin-2 gene modified tumor cells. J Exp Med,1993,177:1127-1134.
14 Horiguchi Y ,Larchian WA,Kaplinsky R,et al. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther,2000,7:844-851.
15 Grote HJ, Schmiemann V, Geddert H, et al. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer.Int J Cancer. 2005; 116(5):720-725.
16 McNeish IA,Bell SJ,Lemoine NR.Gene therapy progress and prospects:cancer gene therapy using tumour suppressor genes.Gene Ther,2004,11(6):497-503.
17 Fodor I,Timiryasova T,Denes B,et al.Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model.J Urol,2005;173(2):604-609.
18 Irie A,Uchida T,Ishida H,et al.p53 Mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells.Mol Uorl,2001,5(2):53-58.
19 Wada Y,Gotoh A,Shirakawa T,et al.Gene therapy for bladder cancer using adenoviral vector.Mol Urol,2001,5(2):47-52.
20 Pagliaro LC.Gene therapy for bladder cancer.World J Urol,2000,18(2):148-151.
21 Xu HJ,Zhou Y,Seigne J,et al.Enhanced tumor suppressor genetherapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein.Cancer Res,1996,56(10):2245-2249.
22 Takino H,Okabe M,Li C,et al.p16/INK4a gene methylation is a frequent finding in pulmonary MALT lymphomas at diagnosis.Mod Pathol.2005;18:1187-1192.
23 GrimJ,D'Amico A,Frizelle S,et al.Adenovirus-mediated delivery of p16 to p16-deficient Human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.Clin Cancer Res,1997,3(12):2415-2423.
24 张海江,王楠,朱晓宇,等.增强p52、p21及抑制c-myc表达对MCF-7细胞增殖的协同抑制作用.实验生物学报,2005;38(1):16-22.
25 Glazko GV,Babenko VN,Koonin EV,et al.Mutational hotspots in the TP53 gene and,possibly,other tumor suppressors evolve by positive selection.Biol Direct,2006,1:4-13.
26 Cairns P,Evron E,Okami K,et al.Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.Oncogene,1998,16:3215-3218.
27 Irie A,Anderegg B,Kashani Sabet M,et al.Therapeutic efficacy of an adenovirusmediated ant-H-ras ribozyme in experimental bladder cancer.Antisense Nucleic Acid Drug Dev,1999,9(4):341-349.
28 Irie A,Kashani-Sabet M,Scanlon KJ,et al.Hammerhead ribozymes as therapeutic agents for bladder cancer. Mol Urol,2000,4(2):61-66.
29 Unfer RC,Hellrung D,Link CJ,et al. Immunity to the alpha(l,3) galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3) galactosyl-transferase: a novel suicide gene for cancer gene therapy, Cancer Res, 2003,63:987-993.
30 Mazzolini G,Prieto J,Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des,2003,9(24):1981-1991.
31 Chan RC,Pang XW,Wang YD,et al. Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells. Br J Cancer,2004,90(8):1636-1463.
32 Larchian WA, Horiguchi Y,Nair SK,et al. Effectiveness of combined interleukin 2 and B7. 1 vaccination strategy is dependent on the sequence and order: a liposome mediaetd gene therapy treatment for blader cancer. Clin Cancer Res, 2000, 6: 2913-2920.
33 Genega EM,Hutchinson B,Reuter VE,et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma .Mod Pathol, 2000, 13(11): 1186-1191.
34 Zhu M Z,Marshall J,Cole D,et al. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res,2000,6 :24-33.
35 Finocchiaro LM,Bumascliny VF,Karara AL,et al. Herpes simplex virus thymidine kinase/ ganciclovir system in multicellular tumor spheroids. Cancer Gene Ther, 2004,11(5) :333-345.
36 Wang Z,Cook T,Alber S,et al. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vasculairty. Cancer Res, 2004,46: 1386-1395.
37 Akasaka S,Suzuki S,Shimizu H,et al. Suicide gene therapy for chemically induced rat bladder tumor entailing instillation of adenoviral vectors. Jpn J Cancer Res, 2001, 92 (5):568 -575.
38 Freund CT,Tong XW,Block A,et al.Adenovirus-mediated suicide gene therapy for bladder cancer:comparison of the cytomegalovirus and Rous sarcoma virus promoter.AnticancerRes,2000,20(5A):2811-2816.
39 Matono S,Tanaka T,Sueyoshi S,et al.Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer.Int J Oncol.2003;23(5):1309-1315.
40 Tanaka M,Fraizer GC,De La Cerda J,et al.Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery.Gene Ther,2001,8:139-148.
41 Walther W,Wendt J,Stein U.Employment of the mdrl promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy.Gene Ther,1997,4:544-552.
42 Griffith TS,Anderson RD,Davidson BL,et al.Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis.J Immunol,2000,165:2886-2894.
43 沈瑞林,金晓东,沈周俊,等.肿瘤坏死因子相关诱导凋亡配体联合化疗药物治疗膀胱癌的研究.中华实验外科杂志,2003,20(9):840-842.
44 沈瑞林,温端改,侯健全,等.真核表达载体Ad-hTRAIL联合丝裂霉素治疗膀胱癌.中华实验外科杂志,2008,25(11):1475-1478.
45 Mizutani Y,Nakao M,Ogawa O,et al.Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.J Urol,2001,165(1):263-270.
46 Oshima Y,Takahashi K,Oshima S,et al.Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization.J Cell Physiol.2004;199(3):399-411.
47 Stilwell JL,McCarty DM,Negishi A,et al.Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.J Virol.2003; 77(23):12881-12885.
48 Xiao W,Chirmule N,Schnell MA,et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther,2000,1:323-329.
49 Naka K, Tachibana A, Ikeda K, et al. Stress-induced premature sensescence in hTERT-expressing ataxia telangiectasia fibroblasts. J Biol chem. 2004, 279(3): 2030-2037.
50 Kraemer K, Fuessel S, Schmidt U, et al.Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res. 2003,9:3794-3800.
51 Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer,1997,33(5):787-791.
52 Nakamura T, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science,1997.277(5328):955-959.
53 Meyerson M, Counter CM, Eaton EN, et al. hEST2,The putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.cell,1977,90(4):785-795.
54 Tahara H, Tahara E, Ide T. Telomere and telomerase associated genes.Gan to kagaku Ryoho,1997,24(15):2196-2201.